Edwards Lifesciences reported Q4 GAAP EPS of $0.11 — missing consensus by 82%. But the same filing reveals 60.5% segment operating margins, among the highest in medtech. The $534 million in litigation, impairments, and restructuring charges that crushed reported earnings mask an adjusted operating margin of 29.4%. The real question isn't whether Edwards is profitable — it's whether the TMTT franchise ($551M, +56.4%) can reach contribution-positive scale before TAVR decelerates, while a $920.8 million tax contingency looms over the fortress balance sheet.
Kenvue reported 41% EPS growth in FY2025 — its best result since separating from Johnson & Johnson. But the metric management actually uses to evaluate the business declined 4.6%. The entire recovery traces to $860 million in non-recurring accounting items: impairment cessation, separation cost winddown, and stock compensation forfeitures. Meanwhile, the company's Skin Health & Beauty segment suffered a 30% two-year profit collapse, three product ingredient categories face simultaneous FDA and litigation scrutiny, and 96% of the company's cash sits overseas — while Kenvue pays out 107.6% of net income in dividends. This is the final independent 10-K of a $15.1 billion consumer health company that has already agreed to be absorbed by Kimberly-Clark for $48.1 billion.
Four hospital operators, four business models, 14x ROIC spread. HCA's scale generates 19.2% returns. THC's ambulatory surgery centers deliver 16.8% margins. UHS's behavioral health focus shows improving trends—but deteriorating litigation risk. CYH's rural model is structurally broken. Static ROIC analysis misses the risk velocity layer that determines which returns are sustainable.
CrowdStrike's 10-Q tells a rare story: risk factors that are actively materializing. Two risks escalated, one is new, and zero have been resolved. The July 19 incident created $101M+ in expenses, litigation with no disclosed maximum exposure, and management admissions that read like warnings, not disclaimers. This is a test case for reading risk factors seriously.
Reddit is playing both sides of the AI data war: licensing to Google and OpenAI for $130M/year while suing Anthropic and Perplexity. SEC filings reveal 'content licensing agreements' driving 'Other revenue' growth. We analyze the dual strategy, quantify the revenue, and assess the legal risk.